Cue Biopharma (NASDAQ:CUE – Get Free Report) and Seres Therapeutics (NASDAQ:MCRB – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, dividends and profitability.
Risk and Volatility
Cue Biopharma has a beta of 2.79, indicating that its stock price is 179% more volatile than the S&P 500. Comparatively, Seres Therapeutics has a beta of 0.44, indicating that its stock price is 56% less volatile than the S&P 500.
Valuation and Earnings
This table compares Cue Biopharma and Seres Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cue Biopharma | $27.47 million | 1.10 | -$26.60 million | ($29.66) | -0.14 |
| Seres Therapeutics | $790,000.00 | 16.11 | $5.70 million | ($5.00) | -0.25 |
Seres Therapeutics has lower revenue, but higher earnings than Cue Biopharma. Seres Therapeutics is trading at a lower price-to-earnings ratio than Cue Biopharma, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
35.0% of Cue Biopharma shares are held by institutional investors. Comparatively, 59.3% of Seres Therapeutics shares are held by institutional investors. 14.6% of Cue Biopharma shares are held by insiders. Comparatively, 5.2% of Seres Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Analyst Ratings
This is a breakdown of recent recommendations for Cue Biopharma and Seres Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cue Biopharma | 1 | 1 | 1 | 0 | 2.00 |
| Seres Therapeutics | 1 | 1 | 2 | 0 | 2.25 |
Cue Biopharma presently has a consensus price target of $83.00, suggesting a potential upside of 1,900.00%. Seres Therapeutics has a consensus price target of $17.00, suggesting a potential upside of 1,261.09%. Given Cue Biopharma’s higher possible upside, equities analysts plainly believe Cue Biopharma is more favorable than Seres Therapeutics.
Profitability
This table compares Cue Biopharma and Seres Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cue Biopharma | -579.95% | -620.87% | -322.13% |
| Seres Therapeutics | -2,209.55% | -194.42% | -58.15% |
Summary
Seres Therapeutics beats Cue Biopharma on 8 of the 14 factors compared between the two stocks.
About Cue Biopharma
Cue Biopharma, Inc. is a biotechnology company developing biologic medicines designed to selectively engage and modulate T cells. Its Immuno-STAT platform is intended to direct immune activity toward disease-specific targets, with potential applications in cancer and autoimmune disorders. The company’s research has included cancer candidates such as CUE-101, designed to target HPV16-positive cancers, and CUE-102, developed to target cancers expressing the WT1 protein. Cue Biopharma has also pursued programs intended to influence immune responses in autoimmune disease.
About Seres Therapeutics
Seres Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing microbiome-based medicines. Its approach uses live biotherapeutic products designed to influence the gut microbiome and address conditions including infections and complications associated with impaired immune function. The company developed VOWST, an oral microbiota-based therapy approved in the United States to prevent recurrent Clostridioides difficile infection in adults after antibacterial treatment.
Receive News & Ratings for Cue Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cue Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
